Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: 86-27-84492310
Tel: 008618986076206
Tel: +86 27 84492310
Tel: WhatsApp +8615927784577
Tel: +8618071739296
Mobile: +8615207100586
Tel: 86-27-84492310
Fax: 86-27-84402310
URL: http://www.vanzpharm.com/en/index.html
Province/state: Hubei
City: JIAYU
Street: FANHU INDUSTRY PARK
MaxCard:
CAS NO.163222-33-1
cas 163222-33-1 99% Ezetimibe powder
Product Name: | Ezetimibe |
CAS: | 163222-33-1 |
MF: | C24H21F2NO3 |
MW: | 409.43 |
EINECS: | 682-606-0 |
What is Ezetimibe
Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors. Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion. It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.
Ezetimibe function
Ezetimibe as the first hypolipidemic drug to act by blocking the absorption of dietary cholesterol. This drug was discovered by Schering-Plough and is codeveloped and co-marketed by Merck and Schering-Plough for the treatment of hypercholesterolemia and also two less common forms of hyperlipidemia: homozygous familial hypercholesterolemia and homozygous sitosterolemia.